Mainstay Medical’s Reactiv8 restorative neurostimulation device for chronic lower back pain earned favorable coverage from Blue Cross Blue Shield of North Dakota, according to a Feb. 6 news release.

Mainstay Medical is a medical device company focused on commercializing its innovative implantable Restorative Neurostimulation TM system, ReActiv8 ®, for people with disabling mechanical CLBP.

Anyone living with chronic low back pain frequently has one wish on their mind: “Fix. My. Lower. Back.” Now, a new clinically proven restorative treatment option called ReActiv8 could make a ...

DUBLIN--(BUSINESS WIRE)--Mainstay Medical Holdings plc today announced the publication of data from a single center, real-world study with one-year clinical follow-up of patients selected from the ...

Chronic lower back pain is something that can dramatically affect a person’s lifestyle and wellbeing. Whilst most back pain only lasts a short while and can be treated with medication or physiotherapy ...

DUBLIN--(BUSINESS WIRE)--Mainstay Medical Holdings plc (the “Company”) today announced the limited commercial launch in the U.S. of ReActiv8, its implantable Restorative Neurostimulation™ system to ...

Mainstay Medical International announced it has submitted a pre-investigation device exemption information package to the U.S. Food and Drug Administration for ReActive8, an implantable ...

ReActiv8 is an implantable medical device designed to treat adults with intractable chronic low back pain (CLBP) associated with multifidus muscle dysfunction. Multifidus muscle dysfunction may be ...

DUBLIN, April 28, 2025--(BUSINESS WIRE)--Mainstay Medical Holdings plc today announced that Anthem Blue Cross and Blue Shield ("Anthem") has established favorable coverage for the company’s ReActiv8 ...